Metacrine Competitors

Metacrine (NASDAQ:MTCR) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Verona Pharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Verona Pharma, as reported by MarketBeat.com.

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Verona Pharma has a consensus price target of $19.00, indicating a potential upside of 137.50%. Given Metacrine's higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Verona Pharma.

Valuation and Earnings

This table compares Metacrine and Verona Pharma's revenue, earnings per share and valuation.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 54.5% of Verona Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metacrine beats Verona Pharma on 4 of the 5 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Spectrum Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Spectrum Pharmaceuticals, as reported by MarketBeat.com.

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Spectrum Pharmaceuticals has a consensus price target of $9.75, indicating a potential upside of 225.00%. Given Metacrine's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Spectrum Pharmaceuticals.

Valuation and Earnings

This table compares Metacrine and Spectrum Pharmaceuticals' revenue, earnings per share and valuation.

Metacrine has higher earnings, but lower revenue than Spectrum Pharmaceuticals.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 63.6% of Spectrum Pharmaceuticals shares are held by institutional investors. 5.0% of Spectrum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metacrine beats Spectrum Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Catalyst Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Catalyst Pharmaceuticals, as reported by MarketBeat.com.

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Catalyst Pharmaceuticals has a consensus price target of $7.6250, indicating a potential upside of 71.73%. Given Metacrine's higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Catalyst Pharmaceuticals.

Valuation and Earnings

This table compares Metacrine and Catalyst Pharmaceuticals' revenue, earnings per share and valuation.

Catalyst Pharmaceuticals has higher revenue and earnings than Metacrine.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 64.9% of Catalyst Pharmaceuticals shares are held by institutional investors. 11.7% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Catalyst Pharmaceuticals beats Metacrine on 6 of the 7 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Verastem's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Verastem, as reported by MarketBeat.com.

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Verastem has a consensus price target of $3.00, indicating a potential upside of 11.94%. Given Metacrine's higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Verastem.

Valuation and Earnings

This table compares Metacrine and Verastem's revenue, earnings per share and valuation.

Metacrine has higher earnings, but lower revenue than Verastem.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 42.2% of Verastem shares are held by institutional investors. 2.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metacrine beats Verastem on 6 of the 8 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Kala Pharmaceuticals (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Kala Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Kala Pharmaceuticals, as reported by MarketBeat.com.

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Kala Pharmaceuticals has a consensus price target of $21.8333, indicating a potential upside of 192.28%. Given Metacrine's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Kala Pharmaceuticals.

Valuation and Earnings

This table compares Metacrine and Kala Pharmaceuticals' revenue, earnings per share and valuation.

Metacrine has higher earnings, but lower revenue than Kala Pharmaceuticals.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 67.6% of Kala Pharmaceuticals shares are held by institutional investors. 34.2% of Kala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metacrine beats Kala Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 66.2% of Altimmune shares are held by institutional investors. 2.7% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Metacrine and Altimmune's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Metacrine and Altimmune's revenue, earnings per share and valuation.

Metacrine has higher earnings, but lower revenue than Altimmune.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Altimmune, as reported by MarketBeat.com.

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Altimmune has a consensus price target of $31.75, indicating a potential upside of 158.76%. Given Metacrine's higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Altimmune.